CD274 and cervical carcinoma: Based on the KEYNOTE-158 clinical trial findings, showing a clinical activity of pembrolizumab in 14% of PDL1-positive patients, the FDA approved pembrolizumab for cervical carcinomas with PDL1 positivity defined by a combined positive score (CPS) ≥ 1 assessed by the DAKO 22C3 assay (75, 76).